Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gyn cancer cells Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, August 04, 2016

Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gyn cancer cells



open access: Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells

 In summary, we demonstrate for the first time that loss of ARID1A leads to accumulation of ROS and suggest that elesclomol may be used to target ARID1A-mutant gynecologic cancer cells.

0 comments :

Post a Comment

Your comments?